DK0569583T3 - Controlled use of polyether-substituted tumor agents in diagnosis and therapy - Google Patents
Controlled use of polyether-substituted tumor agents in diagnosis and therapyInfo
- Publication number
- DK0569583T3 DK0569583T3 DK93901669T DK93901669T DK0569583T3 DK 0569583 T3 DK0569583 T3 DK 0569583T3 DK 93901669 T DK93901669 T DK 93901669T DK 93901669 T DK93901669 T DK 93901669T DK 0569583 T3 DK0569583 T3 DK 0569583T3
- Authority
- DK
- Denmark
- Prior art keywords
- radio
- substituted
- phthalocyanine
- polyethylene glycol
- tumour
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Tumour active or tumour diagnostic compound (I), which concentrates in the tumour, is coupled to a compound (II), with at least two phenolic OH groups or at least one aliphatic amino group, where at least 2 OH or at least 1 NH2 groups are substituted with a polyethylene glycol chain whose polymerisation degree, n, is 5-250, and whose terminal OH group is substituted with a 1-12C alkyl ester or ether. Preferably n = 10-200 (100-110) and (I) is a cis-platin compound, tetracycline, steroid, porphin, phthalocyanine or a conventional X-ray contrast agent. (I) is formed by reacting (II) with the polyethylene glycol ester or ether (III) in solution. When (III) has a molecular weight of more than 5000 (especially more than 10,000) it is activated with cyanuric chloride. - (I) may be radio-labelled, especially as Gd-phthalocyanine metal complexes, Dy164 derivatives of e.g. phthalocyanine or radiolabelled diphosphonates for radiotherapy with L131 or L125, or are conjugated to give radio-iodo, radio-bromo or radio-metal ion activated peptides, porphins or phthalocyanines. Highly iodo-substituted compounds especially porphins and tyrosine oligomers, and boric acid esters, luminols, and radiosensitisers especially nitroimidazoles, in the form of polyethylene glycol derivatives, are also claimed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4139715A DE4139715C2 (en) | 1990-05-30 | 1991-12-02 | Controlled use of polyether-substituted tumor agents in diagnosis and therapy |
PCT/EP1992/002789 WO1993010743A2 (en) | 1991-12-02 | 1992-12-02 | Controlled use of polyether-substituted tumor agents in diagnosis and therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0569583T3 true DK0569583T3 (en) | 2001-11-12 |
Family
ID=6446090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93901669T DK0569583T3 (en) | 1991-12-02 | 1992-12-02 | Controlled use of polyether-substituted tumor agents in diagnosis and therapy |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0569583B1 (en) |
JP (1) | JPH06509117A (en) |
AT (1) | ATE203681T1 (en) |
DE (2) | DE4017439C2 (en) |
DK (1) | DK0569583T3 (en) |
ES (1) | ES2163406T3 (en) |
GR (1) | GR3037077T3 (en) |
PT (1) | PT569583E (en) |
WO (1) | WO1993010743A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2640293B2 (en) * | 1990-05-30 | 1997-08-13 | ドイチエス クレープスフオルシユングスツエントルム ステイフツング デス アフエントリヒエン レヒトス | Polyether-substituted antitumor agent |
DE4017439C2 (en) * | 1990-05-30 | 1994-06-23 | Deutsches Krebsforsch | Polyether-substituted tumor agents |
US5730968A (en) * | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
DE4435087A1 (en) * | 1994-09-30 | 1996-04-04 | Deutsches Krebsforsch | Conjugate for the treatment of infectious, autoimmune and skin diseases |
DE19514087A1 (en) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body |
DE19548114C2 (en) | 1995-12-21 | 2000-04-27 | Deutsches Krebsforsch | Conjugate comprising an active ingredient, a polypeptide and a polyether |
DE19627164C2 (en) * | 1996-07-05 | 1998-09-24 | Deutsches Krebsforsch | Production of polyether-containing chlorins and bacteriochlorins, such compounds and their use |
ATE257014T1 (en) * | 1997-04-29 | 2004-01-15 | Amersham Health As | LIGHT IMAGING CONTRAST AGENTS |
DE10162521A1 (en) * | 2001-12-19 | 2003-07-17 | Goetz Nowak | Use of molecular weight-expanded substances in tumor therapy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062933A (en) * | 1975-05-27 | 1977-12-13 | Mallinckrodt, Inc. | Colloidal compositions with protective agents suitable for radioactive labeling |
US4684728A (en) * | 1979-01-12 | 1987-08-04 | Bayer Aktiengesellschaft | Solubilizing biologically active compounds with reactive hydrogen atoms |
US4615876A (en) * | 1983-04-25 | 1986-10-07 | Curators Of The University Of Missouri | Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides |
US4830847A (en) * | 1985-06-28 | 1989-05-16 | The Procter & Gamble Company | Diphosphonate-derivatized macromolecules |
DE3701665A1 (en) * | 1987-01-19 | 1988-07-28 | Schering Ag | POLYMER COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
DE3809671A1 (en) * | 1988-03-18 | 1989-09-28 | Schering Ag | PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
DE4017439C2 (en) * | 1990-05-30 | 1994-06-23 | Deutsches Krebsforsch | Polyether-substituted tumor agents |
-
1990
- 1990-05-30 DE DE4017439A patent/DE4017439C2/en not_active Expired - Fee Related
-
1992
- 1992-12-02 ES ES93901669T patent/ES2163406T3/en not_active Expired - Lifetime
- 1992-12-02 WO PCT/EP1992/002789 patent/WO1993010743A2/en active IP Right Grant
- 1992-12-02 PT PT93901669T patent/PT569583E/en unknown
- 1992-12-02 JP JP5509832A patent/JPH06509117A/en active Pending
- 1992-12-02 DE DE59209911T patent/DE59209911D1/en not_active Expired - Fee Related
- 1992-12-02 EP EP93901669A patent/EP0569583B1/en not_active Expired - Lifetime
- 1992-12-02 DK DK93901669T patent/DK0569583T3/en active
- 1992-12-02 AT AT93901669T patent/ATE203681T1/en not_active IP Right Cessation
-
2001
- 2001-10-31 GR GR20010401949T patent/GR3037077T3/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1993010743A3 (en) | 1993-07-08 |
DE4017439A1 (en) | 1991-12-05 |
EP0569583B1 (en) | 2001-08-01 |
EP0569583A1 (en) | 1993-11-18 |
DE59209911D1 (en) | 2001-09-06 |
PT569583E (en) | 2002-01-30 |
GR3037077T3 (en) | 2002-01-31 |
WO1993010743A2 (en) | 1993-06-10 |
ATE203681T1 (en) | 2001-08-15 |
DE4017439C2 (en) | 1994-06-23 |
ES2163406T3 (en) | 2002-02-01 |
JPH06509117A (en) | 1994-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920700205A (en) | Tri-aza macrocycle compounds and their metal complexes | |
DK0569583T3 (en) | Controlled use of polyether-substituted tumor agents in diagnosis and therapy | |
AU703057B2 (en) | Improvements in or relating to organic compounds | |
ZA919221B (en) | Drug delivery porphyrin compositions and methods | |
FI935878A (en) | PORFYCENFOERENINGAR FOER FOTODYNAMISK TERAPI | |
KR970701193A (en) | Texaphyrin metal complexes having improved functionalization | |
ATE142508T1 (en) | CONTRAST AGENTS | |
US5622685A (en) | Polyether-substituted porphyrin anti-tumor agents | |
KR900006273A (en) | Chelants having ortho-binding functional groups and complexes thereof | |
US6395254B1 (en) | Conjugate comprising an active agent, a polypeptide and a polyether | |
JPH05501885A (en) | Polyether substituted antitumor agent | |
DK0570575T3 (en) | Bicycloazamacrocyclophosphonic acid, complexes, conjugates, contrast agents and preparation thereof | |
SE9803482D0 (en) | Ion exchange tumor targeting (IETT) | |
ES2107030T3 (en) | 1,1,2-TRIFENILBUTENOS SUBSTITUTED AND ITS USE IN THE TREATMENT AND DIAGNOSIS OF CANCER. | |
DE3473826D1 (en) | N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor | |
MY141501A (en) | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation |